Literature DB >> 30101027

Ruptured hepatoblastoma successfully treated with cisplatin monochemotherapy: A case report.

Tianyou Yang1, Tianbao Tan1, Jiliang Yang1, Jing Pan1, Chao Hu1, Jiahao Li1, Tao Xu2, Yan Zou1.   

Abstract

Traditionally, ruptured hepatoblastoma is considered a high-risk occurrence, necessitating a chemotherapy regimen usually consisting of cisplatin alternating with carboplatin plus doxorubicin, based on International Childhood Liver Tumours Strategy Group studies. However, ruptured hepatoblastomas with intact hepatic capsules may represent a unique subgroup that may be successfully treated with TAE, cisplatin monotherapy, and surgical excision. We herein present a case of ruptured hepatoblastoma (pretreatment tumor extension stage II) in a 1-year-old female patient that was successfully managed with transarterial embolization (TAE), eight courses of cisplatin chemotherapy and surgical removal. The patient currently remains disease-free for >12 months. Given the rarity of ruptured hepatoblastomas, further study of patients within this subgroup is required to confirm the findings of the present study.

Entities:  

Keywords:  chemotherapy; child; ruptured hepatoblastoma; transarterial embolization

Year:  2018        PMID: 30101027      PMCID: PMC6083406          DOI: 10.3892/mco.2018.1643

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  8 in total

1.  Combined treatment of hepatoblastoma with transcatheter arterial chemoembolization and surgery.

Authors:  Jiang Xuewu; Li Jianhong; Hu Xianliang; Chen Zhongxian
Journal:  Pediatr Hematol Oncol       Date:  2006 Jan-Feb       Impact factor: 1.969

2.  Transarterial chemoembolization in the treatment of hepatoblastoma in children.

Authors:  Thomas J Vogl; Albert Scheller; Ursula Jakob; Stefan Zangos; Medhat Ahmed; Mohamed Nabil
Journal:  Eur Radiol       Date:  2005-07-08       Impact factor: 5.315

3.  Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.

Authors:  Josep M Llovet; Maria Isabel Real; Xavier Montaña; Ramon Planas; Susana Coll; John Aponte; Carmen Ayuso; Margarita Sala; Jordi Muchart; Ricard Solà; Joan Rodés; Jordi Bruix
Journal:  Lancet       Date:  2002-05-18       Impact factor: 79.321

4.  The Children's Hepatic tumors International Collaboration (CHIC): Novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model.

Authors:  Piotr Czauderna; Beate Haeberle; Eiso Hiyama; Arun Rangaswami; Mark Krailo; Rudolf Maibach; Eugenia Rinaldi; Yurong Feng; Daniel Aronson; Marcio Malogolowkin; Kenichi Yoshimura; Ivo Leuschner; Dolores Lopez-Terrada; Tomoro Hishiki; Giorgio Perilongo; Dietrich von Schweinitz; Irene Schmid; Kenichiro Watanabe; Marisa Derosa; Rebecka Meyers
Journal:  Eur J Cancer       Date:  2015-12-01       Impact factor: 9.162

Review 5.  Hepatoblastoma state of the art: pre-treatment extent of disease, surgical resection guidelines and the role of liver transplantation.

Authors:  Rebecka L Meyers; Greg Tiao; Jean de Ville de Goyet; Riccardo Superina; Daniel C Aronson
Journal:  Curr Opin Pediatr       Date:  2014-02       Impact factor: 2.856

Review 6.  Malignant tumors of the liver in children.

Authors:  Daniel C Aronson; Rebecka L Meyers
Journal:  Semin Pediatr Surg       Date:  2016-09-04       Impact factor: 2.754

7.  Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study.

Authors:  József Zsiros; Laurence Brugieres; Penelope Brock; Derek Roebuck; Rudolf Maibach; Arthur Zimmermann; Margaret Childs; Daniele Pariente; Veronique Laithier; Jean-Bernard Otte; Sophie Branchereau; Daniel Aronson; Arun Rangaswami; Milind Ronghe; Michela Casanova; Michael Sullivan; Bruce Morland; Piotr Czauderna; Giorgio Perilongo
Journal:  Lancet Oncol       Date:  2013-07-04       Impact factor: 41.316

Review 8.  2005 PRETEXT: a revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group.

Authors:  Derek J Roebuck; Daniel Aronson; Philippe Clapuyt; Piotr Czauderna; Jean de Ville de Goyet; Frédéric Gauthier; Gordon Mackinlay; Rudolf Maibach; Kieran McHugh; Oystein E Olsen; Jean-Bernard Otte; Danièle Pariente; Jack Plaschkes; Margaret Childs; Giorgio Perilongo
Journal:  Pediatr Radiol       Date:  2006-12-21
  8 in total
  1 in total

1.  Outcomes of children with hepatoblastoma who underwent liver resection at a tertiary hospital in China: a retrospective analysis.

Authors:  Jiahao Li; Huixian Li; Huiying Wu; Huilin Niu; Haibo Li; Jing Pan; Jiliang Yang; Tianbao Tan; Chao Hu; Tao Xu; Xiaohong Zhang; Manna Zheng; Kuanrong Li; Yan Zou; Tianyou Yang
Journal:  BMC Pediatr       Date:  2020-05-09       Impact factor: 2.125

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.